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The aim of this study was to explore the influence of testing for hepatitis C virus
(HCV) and perceived HCV status on injecting risk behavior. A cross-sectional,
community-wide survey was undertaken at multiple sites throughout Greater Glasgow
during 2001–2002. Four hundred ninety-seven injecting drug users (IDUs) consented
to participate and were interviewed using a structured questionnaire to ascertain HCV
test history and injecting risk behavior. The average age of participants was 27 years
and the majority of the sample were male (70.4%). Participants had been injecting for
an average duration of 2.5 years. Logistic regression analysis revealed no significant
associations between having been tested and injecting risk behavior. After adjustment
for potential confounding variables, HCV-negatives were significantly less likely to
borrow needles/syringes and spoons or filters as compared with unawares and were
significantly less likely to borrow spoons or filters as compared with HCV-positives.
Due to the cross-sectional design of the study, it is uncertain whether this reduction
in risk behavior could be attributed to perception of HCV status. Further research is
recommended to consolidate the evidence for this relationship.
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 Introduction
Worldwide, it is estimated that around 170 million persons have been infected with the
hepatitis C virus (HCV; World Health Organization [WHO], 1999). In resource-rich coun-
tries such as the UK and the United States, in which an estimated 250,000 and 4 million
persons, respectively, have been infected (Alter et al., 1999; Department of Health, 2004),
the majority of infections have been acquired by injecting drug users (IDUs). Blood tests to
detect past and current infection with HCV became available in the early 1990s and since
then numerous guidelines have recommended that current IDUs should be offered HCV
testing (Scottish Needs Assessment Programme, 2000).
It is recognized that, potentially, there are three benefits of testing: (a) to identify
persons who might be eligible for antiviral therapy, (b) to reduce the risk and rate of
disease progression among those infected by vaccinating them against hepatitis A/B and
advising them against excessive alcohol consumption, and (c) to advise those both with
and without infection against engaging in practices, particularly those relating to inject-
ing drug use, that would result in them transmitting or acquiring infection, respectively
(Goldberg and Anderson, 2004). Apropos current IDUs, reason (a) is usually not relevant
as current injecting is generally a contraindication to therapy (National Institute for Clin-
ical Excellence, 2003) and reason (b) could be achieved without testing for HCV. Reason
(c) is often cited by healthcare professionals as the principal one for HCV testing current
IDUs (Scottish Needs Assessment Programme, 2000). Few evaluations of the impact of
HCV testing in this respect, however, have been undertaken (Aitken, Kerger, and Crofts,
2002; Cook, McVeigh, Syed, Mutton, and Bellis, 2001; Kwiatkowski, Fortuin Corsi, and
Booth, 2002; Malliori et al., 1998; Ompad, Fuller, Vlahov, Thomas, and Strathdee, 2002;
Vidal-Tre´can, Coste, Varescon-Pousson, Christoforov, and Boissonnas, 2000) and those per-
formed were seriously hampered by methodological limitations. Accordingly, the authors
investigated the possibility of associations between self-reported HCV test/perceived result
status and injecting risk behavior among a sample of recent initiates to injecting drug use in
Glasgow.
Methods
Design/Sample
We analyzed data generated through a cross-sectional behavioral survey of IDUs inter-
viewed in Glasgow during 2001 and 2002. Using a community-wide, multiple-site sam-
pling strategy—regarded as the optimal approach for this population group and used pre-
viously on seven occasions in Glasgow since 1990 (Taylor et al., 2000)—497 IDUs were
recruited from needle exchanges (141, 28%), drug treatment agencies (108, 22%), and
street sites (248, 50%) throughout the Greater Glasgow Health Board area. Interviewers
recruited participants between May 2001 and July 2002 and rotated days of the week and
times of the day at which they visited the sites to capture as representative a sample as
possible.
To be eligible for the study, participants were required to have injected drugs on at least
one occasion and to have commenced injecting drugs since January 1, 1997. This date was
chosen because Glasgow has had a well-established network of harm reduction services
(needle exchanges and treatment agencies) since 1996 (Gruer, Cameron, and Elliott, 1993;
Taylor et al., 2000), and one of the main objectives of the survey was to investigate injecting
risk behavior in IDUs since the establishment of these services.
 Data Collection
A questionnaire was administered by trained interviewers, after obtaining informed consent
from the participant. Potential participants were approached, showed an identification card
of the interviewer, and given a brief description of the study. If the individual met the
eligibility criteria, he or she was given an information sheet describing the aims of the study
and the rights of participants. Seven hundred sixty-seven individuals who were approached
to participate were either not eligible or refused. Interviews at street sites were conducted
in a mobile camper van, located in areas of high deprivation and IDU prevalence; those
at drug user treatment agencies and needle exchanges were undertaken in a private room.
Following the interview, participants were given information on obtaining HCV testing and
counseling and drug treatment. Ethical approval for the study was granted from the North
Glasgow LREC Executive Committee.
The questionnaire contained questions about socio-demographic characteristics, injec-
tion history, drug use practices, prison history, attendance at needle exchanges, knowledge
and perceptions of HCV transmission and infection, and testing history for HCV. The ques-
tions relating to injecting risk behavior were derived from a validated questionnaire, the
IRQ (Injecting-Risk Questionnaire), which contains empirically based questions designed
to measure the sharing of injecting equipment. It has previously been assessed with respect
to reliability and validity and found to be highly acceptable for use in a variety of settings
(Stimson, Jones, Chalmers, and Sullivan, 1998). Initials and date of birth were the only
identifiers collected from respondents and, to ensure that no respondent was included more
than once, any apparent duplicates were removed.
Measures
Outcomes. Respondents were asked whether they had engaged in the following risk behav-
iors in the 6 preceding months: (a) injecting with a n/s (needle/syringe) that had previously
been used by someone else (“borrowing n/s”), (b) using spoons or filters into which some-
one else had put a used n/s (“borrowing spoon/filter”), (c) backloading or frontloading (the
process by which drug solute is injected from one n/s into the back or front of another), and
(d) giving, lending, renting, or selling a n/s that had been previously used by the respondent
to others (“lending n/s”). Non-responders were excluded from the analysis.
Exposures. Two exposure variables were considered: having received an HCV test and the
respondent’s perception of his or her HCV status. The latter variable grouped respondents
into three categories—HCV-positives, HCV-negatives, and “HCV-unawares”—based on
their self-reported status. HCV-unawares included those who did not have a test or were not
able to cite their status (either because they could not recall or had not returned to receive
the test result).
Confounding Variables. Variables known or suspected to be associated with injecting risk
behavior or HCV testing were considered as potential confounders in the analyses. These
variables were age, sex, length of injecting career in years, frequency of injection (a proxy
for drug dependence), interviewees’ perception of the prevalence of HCV in Glasgow IDUs
(a proxy for knowledge/perception of the risk of transmission), time taken to get to a needle
exchange (a proxy for access to resources), homelessness, imprisonment, and treatment for
drug use.
 Analysis
Binary logistic regression was used to determine the association between the exposure and
outcome variables. Univariate analyses were conducted by regressing each of the exposure
variables onto each of the outcomes in turn. Multifactorial models were then created by the
addition of the confounding variables to each model. In these analyses, respondents who
had a test within the 6 months prior to the interview were excluded in order to ensure that
the test occurred prior to the injecting risk behavior; this reduced the sample size by 56
individuals (11.7% of the total sample).
Results
The characteristics, injecting risk behaviors, and perceived HCV status of the study partici-
pants are summarized in Table 1. The average age of participants was 27 years and the mean
length of injecting career was 2.5 years. The majority of the sample were male (70.4%)
and had ever been in treatment for drug use (84%), and more than half the sample was
currently receiving treatment. Most respondents reported having injected heroin in the 6
months prior to interview (442, 89%), followed by cocaine (168, 34%) and temazepam (95,
19%). Over 50% reported having been imprisoned since commencing injecting drug use.
The primary place of residence in the past 6 months varied, with the largest percentage of
respondents reporting living in their own home, followed by someone else’s home, and a
hostel for the homeless. Sixty-two percent of respondents reported injecting at least twice
a day. The majority (80.5%) of respondents reported less than 30 minutes travel time to the
nearest needle exchange. When asked to estimate the number of HCV-infected Glasgow
IDUs out of 100, 60% of respondents estimated the prevalence to be 75% or greater.
In terms of HCV test uptake, nearly half (48.8%) of respondents reported having ever
received a test. Thirteen percent of all respondents cited a positive test result, 25.8% cited
a negative result, and the remaining respondents could not cite their status. Injecting risk
behaviors were markedly prevalent in the sample: the proportions of those having lent
or borrowed injecting equipment ever and in the last 6 months ranged from 54 to 78%
and 40 to 60% respectively. Backloading/frontloading was not as common, with 36.3% of
respondents reporting having ever engaged in this behavior. Fewer respondents reported
engaging in these injecting risk behaviors in the 6 months prior to the interview, yet the
behaviors were nevertheless quite common, with 43.9% of respondents reporting having
shared n/s, 60.2% having shared spoons or filters, 24.1% having backloaded/frontloaded,
and 39.6% having passed on n/s.
The results of the unadjusted and adjusted analyses of the association between hav-
ing received an HCV test and injecting risk behavior are presented in Table 2. Those
who had previously been tested for HCV had lower odds of engaging in all types of
injecting risk behavior relative to those who had never been tested, although none of
the associations reached statistical significance, even after adjustment for confounding
variables.
The results of the unadjusted and adjusted analyses of the association between perceived
HCV status and injecting risk behavior are presented in Table 3. Relative to unawares, HCV-
negatives were significantly less likely to have borrowed n/s (adjusted OR = 0.52, p = 0.027)
and spoons or filters (adjusted OR = 0.46, p = 0.008). Relative to HCV-negatives, HCV-
positives were significantly more likely to have borrowed spoons or filters (adjusted OR
= 4.81, p = 0.004) but not n/s (OR = 1.57, p = 0.355). No significant associations were
observed for backloading or frontloading. Relative to unawares, HCV-positives were less
 Table 1
Characteristics, injecting risk behaviors, and perceived HCV status among 497 IDUs, who
had commenced injecting since January 1, 1997, surveyed in Glasgow, 2001–2002
Characteristic Mean (SD)
Age at recruitment into study (years) 27.1 (5.4)
Length of injecting career (years) 2.5 (1.6)
Characteristic N (%)
Male sex 349 (70.4%) (non-responses = 1)
Ever been in treatment for drug use 409 (84.0%) (non-responses = 10)
Currently in treatment for drug use 270 (55.3%) (non-responses = 9)
Imprisoned since commenced injecting 264 (53.7%) (non-responses = 5)
Primary place of residence in past 6 months
Own home 162 (32.6%)
Someone else’s home 126 (25.4%)
Homeless hostel 114 (22.9%)
No fixed abode 39 (7.8%)
Prison 34 (6.8%)
Other 22 (4.4%)
Frequency of injection
Once per day 176 (38.3%)
2–3 Times per day 175 (38.1%)
>3 Times per day 108 (23.5%)
(non-responses = 38)
Time taken to get to needle exchange
0–14 Minutes 203 (50.1%)
15–29 Minutes 123 (30.4%)
30–44 Minutes 66 (16.3%)
45+ Minutes 13 (3.2%)
(non-responses = 92)
Interviewee’s estimated prevalence of HCV in Glasgow IDUs
<50% Prevalence 46 (10.3%)
50–75% Prevalence 132 (29.7%)
75%+ Prevalence 267 (60.0%)
(non-responses = 52)
Perceived HCV status N (%)
Previous HCV test 233 (48.8%)
(non-responses = 20)
Perceived HCV status
Positive 64 (12.9%)
Negative 128 (25.8%)
Unaware∗∗ 305 (61.4%)
Risk behavior Ever (N, %) Last 6 months (N, %)
Borrowed used n/s 324 (65.9%)
(non-responses = 5)
217 (43.9%)
(non-responses = 3)
Borrowed used spoon/filter 390 (78.5%)
(non-responses = 0)
299 (60.2%)
(non-responses = 0)
Backloaded/frontloaded 178 (36.3%)
(non-responses = 6)
119 (24.1%)
(non-responses = 4)
Lent n/s∗ 264 (53.8%)
(non-responses = 6)
194 (39.6%)
(non-responses = 7)
∗Given/lent/rented/sold a n/s previously used by the respondent to another user.
∗∗Includes non-responders, those who did not have a test, those who did not receive test result, and
those who could not recall test result.
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 likely to have lent n/s, an association which almost reached significance (adjusted OR =
0.45, p = 0.058).
Discussion
This analysis did not reveal any statistically significant differences in injecting risk behavior
between those who reported having previously received a test for HCV compared with those
who had not. This observation was in contrast to previous findings (Aitken et al., 2002; Cook
et al., 2001), which described a benefit of testing in terms of reducing subsequent injecting
risk behavior. A possible reason for the lack of observed differences in the current analysis is
that the classification of individuals as either tested or untested might have concealed those
differences, since individuals who were tested but did not receive the result would have been
assigned to the tested category. It has been suggested that it is the outcome of the test that
has implications for risk behavior (Weinstein, Rothman, and Nicolich, 1998); accordingly,
when risk behavior was examined in relation to perceived HCV status in the current analy-
sis, some significant associations were found. After adjustment for confounding variables,
HCV-negatives were approximately half as likely to borrow n/s or spoons/filters relative
to those who were unaware of their status. It could be hypothesized that HCV-negatives
were motivated to reduce their borrowing of injecting equipment in order to preserve their
negative status. This association was not observed for the lending of n/s, which is consistent
with the hypothesis, since the individual would not be incurring or conveying any risk of
infection by lending a n/s to another user. The results do not lend support to the supposi-
tion advanced by previous authors that, after being notified of an HCV-negative result, the
individual might feel that he/she is somehow resilient to infection and continue to engage
in the same high-risk drug injecting practices as before testing (Brogly, Bruneau, Lamothe,
Vincelette, and Franco, 2002).
No significant associations were found in the comparison of HCV-positives relative to
unawares, although the observation that HCV-positives were less likely to lend n/s was very
nearly significant. Since a reduction in lending would confer no benefit to the individual, it
suggests that perceived positive status might inspire altruistic behaviour and is consistent
with the finding of Kwiatkowski et al. (2002) that a lower proportion of IDUs who were
aware of their positive status had lent n/s within the month prior to interview compared to
IDUs who were unaware of their positive status.
In the comparison of HCV-positives and -negatives, we found that HCV-positives were
significantly more likely to borrow spoons or filters than HCV-negatives. Again, these
behaviors put the individual who is accepting the drug equipment at risk of infection and is
consistent with the previous argument that HCV-negatives would be less likely to engage
in these behaviors in order to preserve their negative status.
With respect to backloading/frontloading, no significant associations were observed for
any of the comparisons. The absence of any observed associations may be due to a lack of
statistical power, since backloading/frontloading was only reported by a small percentage
of respondents.
It should be emphasized that the HCV-negative or HCV-positive result used in this
analysis was the status reported by the respondent. Self-reported status may not have re-
flected true status (Cook et al., 2001; Stein, Maksad, and Clarke, 2001), either because the
individual incorrectly understood the results of a test or became infected after receiving a
negative test result. Such discrepancies would not have compromised the analysis since it
was the participant’s perception of his HCV result status, rather than his true status, that
mattered, apropos associations with injecting risk behavior.
 The validity and reliability of retrospective self-report data obtained from injecting
drug users may be questionable due to recall and/or social desirability biases. However,
numerous studies support the use of this method in terms of both reliability (Brown, Kranzler,
and Del Boca, 1992; Goldstein et al., 1995; McElrath, Chitwood, Griffin, and Cornerford,
1994) and validity (Brown et al., 1992). In addition, the current research took all reasonable
measures to reduce socially desirable responses by collecting only initials and date of birth as
personal identifiers, assuring participants of anonymity, and conducting interviews in private
settings.
The analysis excluded respondents who received a test within the 6 months prior to
the interview in an attempt to ensure that the test occurred prior to the risk behavior. It
should nevertheless be recognized that an observational study design allows associations
but not conclusions regarding any cause and effect to be determined. It is quite possible,
for example, that injectors perceiving themselves to be HCV-negative were more likely
to subsequently engage in less risky behavior than those unaware of their HCV status
because of factors unrelated to HCV testing, such as HIV testing, or some other health care
intervention. As those who have been tested for HCV are also more likely to have had an
HIV test, we cannot exclude the possibility that changes in risk behavior might have been
motivated by perceptions or fear of HIV infection. Other study limitations included lack
of information about the knowledge, if any, imparted by the health care professionals who
were directly involved with the participant in the HCV testing process. If participants were
tested but not informed of the risks or consequences of HCV infection, then knowing one’s
status would not necessarily translate into behavioral changes.
Due to the cross-sectional nature of the survey, the possibility that the associations
observed operate in the opposite direction, i.e., that perceived HCV-negative individuals
are indeed negative as a result of having engaged in less risk behavior in the past, cannot be
excluded. A longitudinal study design is preferable to determine the direction of associations
and has previously been carried out in this context (Aitken et al., 2002; Ompad et al.,
2002); however, issues with respect to this type of design include the substantial difficulties
associated with follow-up in the IDU population.
Despite the aforementioned limitations, the current analysis has several strengths. The
sample size was similar to, or larger than, all of those generated in the context of previous
studies of HCV test result status and behaviour among injecting drug users (Aitken et al.,
2002; Cook et al., 2001; Kwiatkowski et al., 2002; Malliori et al., 1998; Ompad et al., 2002;
Vidal-Tre´can et al., 2000). This analysis distinguished between borrowing vs. lending be-
haviors and borrowing n/s vs. borrowing injecting equipment, activities that have previously
been combined in some studies. After Vidal-Tre´can et al. (2000), this analysis is only the
second of the aforementioned studies to have considered the role of potential confounding
variables. The study also employed a comprehensive sampling strategy, similar to that un-
dertaken by Cook et al. (2001). As such, the sample was more likely than those from most
previous studies to be representative of the IDU population. However, since the study’s
inclusion criteria limited the sample to recent initiates, the extrapolation of the results of
this analysis to other IDU populations should be undertaken with caution.
This analysis has contributed to the small body of evidence on the relationship between
HCV test/result status and injecting risk behavior. The findings of the current analysis did
not provide evidence of a benefit of testing per se but did lend some support to the theory
that HCV status perception affects injecting risk behavior. In spite of this, the results are
still largely inconclusive and further research is required to evaluate properly the impact of
HCV testing on injecting risk behavior. Future studies should be longitudinal in design and
involve larger samples to increase precision.
 In the meantime, however, what should our policy be, regarding HCV testing of IDUs?
The results of the current analysis as well as previous research indicate that knowledge of
one’s HCV status in this population is indeed very limited. While the evidence of any major
benefit to current IDUs of HCV testing is currently lacking, there is none to suggest that
testing promotes risky injecting behaviour. Accordingly, it would be reasonable to advocate
(a) the offer, without strong recommendation, of an HCV test to all current injectors; and (b)
the offer, with strong recommendation, of a test to former injectors. The subtle difference
reflects the importance of identifying individuals likely to (a) be infected with HCV, (b)
have moderate or severe hepatitis and, (c) have no contraindications, such as chaotic current
injecting, to receiving antiviral therapy.
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R ´ESUM ´E
Exploration des associations entre le statut perc¸u d’infection avec l’he´patite C et les
comportements a` risque dans un e´chantillon d’utilisateurs de drogues injectables a`
Glasgow
Cette e´tude a pour objectif d’examiner l’influence du testage pour l’he´patite C et de
la perception de statut sur le comportement a` risque. Nous avons entrepris un sondage
communautaire d’utilisateurs de drogues injectables (UDI); 497 UDI recrute´s dans divers
lieux a` Glasgow pendant 2001–2002 ont donne´ leur accord et participe´ aux entretiens.
L’age moyen des participants e´tait de 27 ans et la plus grande partie e´tait des hommes
(70.4%). En moyenne, les participants avaient utilise´ des drogues pour une dure´e de 2.5
ans. Les analyses de re´gression logistique n’ont pas de´montre´ d’associations entre le testage
pour l’he´patite C et le comportement a` risque. Apre`s avoir ajuste´ notre analyse pour les
variables confondantes, les participants qui se percevaient ne´gatifs pour l’he´patite C e´taient
significativement moins a` risque d’avoir emprunte´ des seringues et des cuille`res/filtres que
ceux qui e´taient me´connaissants, et significativement moins a` risque d’avoir emprunte´ des
cuille`res/filtres que ceux qui se croyaient positifs. Puisqu’il s’agit ici d’un e´chantillon, on
ne peut pas conclure avec certitude que la re´duction du comportement a` risque peut eˆtre
attribue´e a` la perception de statut de l’he´patite C et des recherches supple´mentaires sont
recommande´es afin de consolider nos connaissances actuelles.
RESUMEN
Asociaciones que exploran entre el estado de HCV y los comportamientos percibidos
del Inyectar-Riesgo entre iniciados recientes al uso de la droga que inyecta en
Glasgow
La punterı´a de este estudio era explorar la influencia de la prueba para el virus de
la hepatitis C (HCV) y del estado percibido de HCV en comportamiento del inyectar-
riesgo. Un examen seccionado transversalmente, a nivel comunitario fue emprendido en
 los sitios mu´ltiples a trave´s de mayor Glasgow durante 2001–2002. Cuatro cientos y ninety-
seven inyectando a usuarios de droga (IDUs) consintieron participar y fueron entrevistados
con usando un cuestionario estructurado para comprobar historia de la prueba de HCV
y comportamiento del inyectar-riesgo. La edad media de participantes era 27 an˜os y la
mayorı´a de la muestra era masculina (70.4%). Los participantes habı´an estado inyectando
para una duracio´n media de 2.5 an˜os. El ana´lisis logı´stico de la regresio´n no revelo´ ninguna
asociacio´n significativa entre la prueba y el comportamiento del inyectar-riesgo. Despue´s del
ajuste para las variables de la confusio´n del potencial, HCV-negatives eran perceptiblemente
menos probables pedir prestado needles/syringes y las cucharas o los filtros con respecto a
unawares, y eran perceptiblemente menos probables pedir prestados las cucharas o los filtros
con respecto a HCV-positives. debido al disen˜o seccionado transversalmente del estudio,
es incierto si esta reduccio´n en comportamiento del riesgo se podrı´a atribuir a la opinio´n
del estado de HCV. La investigacio´n adicional se recomienda para consolidar la evidencia
para esta relacio´n.
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Glossary
Backloading/Frontloading: the process by which drug solute is injected from one n/s into
the back or front of another.
HCV: hepatitis C virus.
IDU: injecting drug user.
Injecting-Risk Behavior: sharing needles/syringes or other injecting equipment, or back-
loading or frontloading.
n/s: needles/syringes.
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